Stemline Therapeutics Inc (STML) Receives Consensus Rating of “Buy” from Analysts

Stemline Therapeutics Inc (NASDAQ:STML) has been given an average recommendation of “Buy” by the eight ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $33.75.

A number of analysts have weighed in on the company. Zacks Investment Research downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 9th. HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of Stemline Therapeutics in a research report on Friday, February 2nd. ValuEngine raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BidaskClub raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 26th.

In related news, COO Kenneth Hoberman sold 11,943 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $14.18, for a total value of $169,351.74. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David Gionco sold 4,250 shares of the firm’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $13.43, for a total transaction of $57,077.50. The disclosure for this sale can be found here. Insiders have sold a total of 42,216 shares of company stock worth $591,925 in the last three months. Insiders own 15.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC lifted its position in Stemline Therapeutics by 1.3% in the 2nd quarter. Teachers Advisors LLC now owns 43,397 shares of the biopharmaceutical company’s stock valued at $399,000 after acquiring an additional 541 shares in the last quarter. Nationwide Fund Advisors lifted its position in Stemline Therapeutics by 7.2% in the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 855 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Stemline Therapeutics by 40.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 5,522 shares in the last quarter. Royce & Associates LP bought a new position in Stemline Therapeutics in the 4th quarter valued at about $106,000. Finally, Schwab Charles Investment Management Inc. lifted its position in Stemline Therapeutics by 17.0% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 47,025 shares of the biopharmaceutical company’s stock valued at $734,000 after acquiring an additional 6,825 shares in the last quarter. 42.85% of the stock is currently owned by institutional investors and hedge funds.

Shares of Stemline Therapeutics (NASDAQ:STML) opened at $15.55 on Wednesday. Stemline Therapeutics has a 1-year low of $6.35 and a 1-year high of $17.40. The firm has a market capitalization of $450.51, a PE ratio of -6.05 and a beta of -0.02.

TRADEMARK VIOLATION NOTICE: This report was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/14/stemline-therapeutics-inc-stml-receives-consensus-rating-of-buy-from-analysts.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply